AI assistant
Sending…
Monopar Therapeutics — Director's Dealing 2023
Feb 4, 2023
32883_dirs_2023-02-03_8224a523-26d3-4518-9e68-6490ad5dde25.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Monopar Therapeutics (MNPR)
CIK: 0001645469
Period of Report: 2023-02-01
Reporting Person: STARR CHRISTOPHER M (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-02-01 | Stock Options | $3.16 | A | 13930 | Acquired | 2033-02-01 | Common Stock (13930) | Direct |
| 2023-02-01 | Restricted Stock Units | $0 | A | 10133 | Acquired | Common Stock (10133) | Direct |
Footnotes
F1: Options vest 25% quarterly on March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023.
F2: RSUs vest 25% quarterly on March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023.